Anti-CD40 Therapy in Sjögren's Disease Iscalimab, a CD40 monoclonal antibody, showed + results in treating Sjögren's disease, an autoimmune condition lacking effective therapy. The TWINSS study demonstrated iscalimab's safety/efficacy in a phase 2 trial. https://t.co/aanI9K83XP https://t.co/qJhgHDFCVY